China's National Medical Products Administration accepted Shijiazhuang Yiling Pharmaceutical's (SHE:002603) clinical trial application for LB220-D08 extended-release tablets, according to a Shenzhen bourse filing on Thursday.
The drug will be tested as a treatment for atypical hemolytic uremic syndrome.
The pharmaceutical company's shares rose 3% in the afternoon trade.